Please assess the completion status of the following clinical trial:

Trial Title: Bone and Body Comp: A Sub Study of the SECOND-LINE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Second-Line main study identifier: NCT00931463~Inclusion Criteria:~1. HIV-1 positive by licensed diagnostic test~2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)~3. Have received first antiretroviral regimen consisting of an NNRTI plus 2N(t)RTIs for ≥ 24 weeks~4. No change in antiretroviral therapy within 12 weeks prior to screening~5. Failed first-line NNRTI + 2N(t)RTI combination therapy according to virological criteria defined by two consecutive (≥7 days apart) HIV RNA results of \> 500 copies/mL~6. No prior or current exposure to HIV protease inhibitors and/or HIV integrase inhibitors~7. Able to provide written informed consent~Exclusion Criteria:~1. The following laboratory variables:~   * absolute neutrophil count (ANC) \< 500 cells/µL~  * hemoglobin \< 7.0 g/dL~  * platelet count \< 50,000 cells/µL~  * ALT \> 5 x ULN~2. Pregnant or nursing mothers~3. Participants with active viral hepatitis B infection defined by the presence in serum of hepatitis B surface antigen~4. Use of immunomodulators within 30 days prior to screening~5. Use of any prohibited medications (rifampicin, midazolam, triazolam, cisapride, pimozide, amiodarone, dihydroergotamine, ergotamine, ergonovine, methylergonovine, astemizole, terfenadine, vardenafil, and St. John's wort)~6. Intercurrent illness requiring hospitalisation~7. Active opportunistic disease not under adequate control in the opinion of the site Principal Investigator~8. Participants with current alcohol or illicit substance abuse that in the opinion of the site Principal Investigator might adversely affect participation in the study~9. Participants deemed by the site Principal Investigator unlikely to be able to remain in follow-up for the protocol-defined period

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI (Type: ACTIVE_COMPARATOR): LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
- Arm 2. Lopinavir /ritonavir + raltegravir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).